Hisamitsu boosts shareholder value, invests in directors, reorganizes capital

Hisamitsu Pharmaceutical Co., Inc. today announced a series of strategic initiatives aimed at enhancing shareholder value and incentivizing company leadership. The company will acquire up to 3 million of its own shares, representing 4.09% of outstanding shares (excluding treasury shares), for a maximum of JPY15 billion, between July 11 and December 31, 2025. The shares will be acquired through off-auction and open market transactions. The company also intends to cancel an equal number of treasury shares, acquired in this round, to further increase shareholder value.